Multicenter, USA - 04 Apr `17Incyte: A Study of Ruxolitinib 1,5% cream

Official Title: A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

In Brief: The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Description: Ruxolitinib cream 1.5% twice-daily for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension

Details: Check Incyte announcement or download pdf with a scientific presentation from UMass.

Ages Eligible: 18 Years to 75 Years

Start Date: April 19, 2017

Completion Date (estimated): September 2021

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03099304
Other Study ID Numbers: INCB 18424-211 

Location: 26 locations across the United States

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...